Opus Genetics Inc
NASDAQ:IRD

  • LAST PRICE
    1.0100
  • TODAY'S CHANGE (%)
    0.0259 (2.6318%)
  • Bid / Lots
    1.0200/ 1
  • Ask / Lots
    1.0400/ 1
  • Open / Previous Close
    0.9900 / 0.9841
  • Day Range
    0.9800
    1.0124
  • 52 Week Range
    0.8531
    3.3994
  • Volume
    295,328

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 12, 2024

      Show headlines and story abstract

    • 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
      Companies Mentioned: IRD

    • 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
      Companies Mentioned: IRD
      2024 2023 2024 2023 ----------- ----------- ----------- ----------- License and collaborations revenue $ 3,867 $ 11,935 $ 6,690 $ 17,358 Operating expenses: General and administrative 2,894 2,055 10,918 8,680 Research and development 8,982 3,494 19,817 13,812 ---------- ---------- ---------- ---------- Total operating expenses 11,876 5,549 30,735 22,492 ---------- ---------- ---------- ---------- (Loss) income from operations (8,009) 6,386 (24,045) (5,134) Financing costs -- (1,328) -- (1,328) Fair value change in derivative liability -- 61 -- 61 Other income, net 483 456 1,648 1,224 ---------- ---------- ---------- ---------- (Loss) income before income taxes (7,526) 5,575 (22,397) (5,177) Provision for income taxes -- (14) -- (14) ---------- ---------- ---------- ---------- Net (loss) income (7,526) 5,561 (22,397) (5,191) ---------- ---------- ---------- ---------- Other comprehensive (loss) income, net of tax -- -- -- -- ---------- ---------- ---------- ---------- Comprehensive (loss) income $ (7,526) $ 5,561 $ (22,397) $ (5,191) ========== ========== ========== ========== Net (loss) income per share: Basic $ (0.29) $ 0.26 $ (0.88) $ (0.25) ========== ========== ========== ========== Diluted $ (0.29) $ 0.25 $ (0.88) $ (0.25) ========== ========== ========== ========== Number of shares used in per share calculations: Basic 26,145,080 21,446,648 25,501,117 21,117,211 Diluted 26,145,080 22,405,995 25,501,117 21,117,211 ========== ========== ========== ==========

    • 7:59AM ET on Tuesday Nov 12, 2024 by Dow Jones
      Companies Mentioned: IRD

      Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      FARMINGTON HILLS, Mich., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other ophthalmological disorders (the "Company"), today announced that the independent members of its Board of Directors approved an equity award under the Company's 2021 Inducement Plan, as amended, as a material inducement to Dr. Benjamin Yerxa, Ph.D., the Company's newly appointed President, in connection with his employment with the Company, effective November 7, 2024. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of any equity awards that are not made under a stockholder approved equity plan.

    • 7:59AM ET on Tuesday Nov 12, 2024 by Dow Jones
      Companies Mentioned: IRD

      Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      FARMINGTON HILLS, Mich., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other ophthalmological disorders (the "Company"), today announced that the independent members of its Board of Directors approved an equity award under the Company's 2021 Inducement Plan, as amended, as a material inducement to Dr. Benjamin Yerxa, Ph.D., the Company's newly appointed President, in connection with his employment with the Company, effective November 7, 2024. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of any equity awards that are not made under a stockholder approved equity plan.

Peers Headlines